Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck Cancer

被引：3
|
作者：
Clark, Joseph I. [1 ,2 ]
Eisner, Robert M. [1 ]
Hofmeister, Craig [3 ]
Norton, John [1 ]
Thomas, Sachdev [1 ]
Choudhury, Abdul [2 ]
Petruzzelli, Guy [4 ]
Lathers, Deanne [5 ]
Young, M. Rita I. [5 ,6 ]
Lau, Ann [1 ]
Emami, Bahman [7 ]
机构：
[1] Loyola Univ, Med Ctr, Dept Med, Div Hematol Oncol,Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA
[2] Jr Hines VA Hosp, Med Serv, Hines, IL USA
[3] Ohio State Univ, Dept Hematol, Columbus, OH 43210 USA
[4] Rush Univ, Med Ctr, Dept Otolaryngol, Chicago, IL 60612 USA
[5] Ralph H Johnson VA Med Ctr, Dept Otolaryngol, Res Serv, Charleston, SC USA
[6] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA
[7] Loyola Univ, Med Ctr, Dept Radiat Oncol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA
来源：
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2009年 / 32卷 / 04期
关键词：
phase I; radiochemotherapy; docetaxel; high risk; head and neck cancer; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; ACTIVE-DRUG; CHEMOTHERAPY; FLUOROURACIL; CISPLATIN; INFUSION; TRIAL;
D O I：
10.1097/COC.0b013e31818da9c7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: This phase I study was designed to determine the maximum tolerated dose (MTD) and preliminary efficacy of docetaxel with concurrent radiotherapy (RT), in high-risk squamous cell carcinoma of the head and neck. Patients and Methods: Eligible patients had resected squamous cell carcinoma of the head and neck, histologically involved lymph nodes, and/or extranodal disease, and/or involved surgical margins and performance status 0 to 1. Treatment included weekly docetaxel with concurrent RT in a dose-finding study; a subsequent small cohort of patients was treated using the MTD of docetaxel. Results: Twenty patients were enrolled. Planned accrual was 25, but the study was closed prematurely because of slow accrual. The MTD was 15 mg/m(2). Dose-limiting toxicity was oral stomatitis. Therapy was well tolerated. Five patients experienced locoregional relapse at a median follow-up of 32 months. Conclusion: Docetaxel with concurrent RT has acceptable toxicity. This approach warrants further investigation in a phase II trial.
引用
收藏
页码：396 / 400
页数：5
相关论文
共 50 条
  • [41] A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck
    Margalit, Danielle N.
    Haddad, Robert I.
    Tishler, Roy B.
    Chau, Nicole G.
    Schoenfeld, Jonathan D.
    Bakst, Richard L.
    Misiukiewicz, Krzysztof J.
    Gupta, Vishal
    Posner, Marshall
    Hanna, Glenn J.
    Mahmood, Umair
    Rawal, Bhupendra
    Catalano, Paul J.
    Rath, Lynda
    Bacay, Alyssa
    McHugh, Patricia
    Rabinowits, Guilherme
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : 132 - 139
  • [42] Definitive Radiochemotherapy of Advanced Head and Neck Cancer with Carboplatin and Paclitaxel A Phase II Study
    Semrau, Robert
    Temming, Susanne
    Preuss, Simon Florian
    Klussmann, Jens Peter
    Guntinas-Lichius, Orlando
    Mueller, Rolf-Peter
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (10) : 645 - 650
  • [43] Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancer
    Dragovic, Aleksandar F.
    Caudell, Jimmy J.
    Spencer, Sharon A.
    Carroll, William R.
    Nabell, Lisle A.
    Bonner, James A.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2013, 35 (03): : 381 - 387
  • [44] Toxicity of Induction Chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil for Advanced Head and Neck Cancer
    Billan, Salem
    Kaidar-Person, Orit
    Atrash, Fadi
    Doweck, Ilana
    Haim, Nissim
    Kuten, Abraham
    Ronen, Ohad
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2013, 15 (05): : 231 - 235
  • [45] Neoadjuvant dose-modified docetaxel in squamous cell carcinoma of the head and neck: A phase 3 study
    Sun, Yan
    Guo, Wei
    Bai, Yuxian
    Ge, Minghua
    Hu, Chaosu
    Wu, Shaoxiong
    Hao, Junfang
    Gao, Ming
    Pan, Jianji
    Dong, Pin
    Wu, Yunong
    Liang, Houjie
    Wei, Qichun
    Zhong, Meizuo
    Lu, Taixiang
    ORAL DISEASES, 2020, 26 (02) : 285 - 294
  • [46] Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer
    Tahara, M.
    Araki, K.
    Okano, S.
    Kiyota, N.
    Fuse, N.
    Minashi, K.
    Yoshino, T.
    Doi, T.
    Zenda, S.
    Kawashima, M.
    Ogino, T.
    Hayashi, R.
    Minami, H.
    Ohtsu, A.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 175 - 180
  • [47] Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: phase I study of the Shiga Breast Cancer Study Group
    Abe, Hajime
    Ogawa, Hiroki
    Okino, Takashi
    Kato, Makoto
    Sako, Hirotaka
    Sano, Haruo
    Shimomatsuya, Takumi
    Suwa, Hirofumi
    Higashide, Shunichi
    BREAST CANCER, 2009, 16 (01) : 37 - 41
  • [48] Adjuvant docetaxel and carboplatin chemotherapy for patients with high-intermediate and high-risk endometrial cancer
    Kudaka, W.
    Nakasone, T.
    Arakaki, Y.
    Nakamoto, T.
    Wakayama, A.
    Kinjyo, Y.
    Taira, Y.
    Nagai, Y.
    Kaneshima, I.
    Nishihira, K.
    Aoki, Y.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2017, 38 (06) : 917 - 920
  • [49] Adjuvant simultaneous integrated boost IMRT for patients with intermediate- and high-risk head and neck cancer: Outcome, toxicities and patterns of failure
    Stromberger, Carmen
    Jann, David
    Becker, Eva-Tessina
    Raguse, Jan-Dirk
    Tinhofer, Ingeborg
    Marnitz, Simone
    Budach, Volker
    ORAL ONCOLOGY, 2014, 50 (11) : 1114 - 1121
  • [50] Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer
    Park, Robin
    Park, Jong Chul
    IMMUNOTHERAPY, 2021, 13 (11) : 931 - 940
12345